3 Reasons the mRNA-4157 Readout Could Revalue Moderna

Moderna is shifting from a COVID cash cow to a pipeline-driven biotech.
The registrational readout for mRNA-4157 with Merck is the biggest catalyst and risk.
– Analysts’ view: Motley Fool segment averaged a 6.3/10 score with mixed ratings across business, management, financials, and safety.
– Catalyst focus: mRNA-4157 registrational data expected later this year; success could materially re-rate the stock, failure would hurt valuation.
– Financial runway: roughly $8.1 billion in cash and a forecasted ~$2 billion in revenue this year provide a cushion but profitability is years away.
– Operational concerns: prior manufacturing overcapacity, an FDA refusal-to-file on the flu program, and concentrated mRNA platform risk.
– Investor takeaway: high-risk, high-reward exposure—size positions accordingly and consider diversifying with peers like BioNTech.
————————————————————————
This video is brought to you by The Motley Fool.
Visit https://fool.com/Invest to get access to this special offer. The Motley Fool Stock Advisor returns are 929% as of 7/13/2026 and measured against the S&P 500 returns of 211% as of 7/13/2026. Past performance is not an indicator of future results. All investing involves a risk of loss. Individual investment results may vary, not all Motley Fool Stock Advisor picks have performed as well.
————————————————————————